Ann: Three Complete Responses in Azer-Cel Phase 1b Trial, page-236

Now that some of the dust has settled, an interesting announcement for Azercel.

Group A really not that flash.
6 patients, 1 complete response, 1 partial response. 4 patients no response at all.

Group B, small sample sample size but looking blockbuster
3 patients, 2 complete response, 1 stable disease - which may yet get upgraded (believed pseudo progression).

Looks like Interleukin is the secret sauce to keep the T cells alive and active.

And to put the rumours to bed. No patients withdraw in either group due to toxicity. So Azercel is looking very safe.


To me looks like group B was a pivot from the team mid trial. And if so, proves their brilliance as research doctors and bio science experts.

Just a shame there wasn't a couple more patient data in group B.

IMO Azercel with Interleukin is very much on track for a registrational phase 2 trial and FDA fast track.

DYOR not advice.